# Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma

> **NCT07321912** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Milton S. Hershey Medical Center** · enrollment: 406 (estimated)

## Conditions studied

- Osteosarcoma
- Ewing Sarcoma
- Ewing Sarcoma Metastatic

## Interventions

- **DRUG:** Eflornithine
- **DRUG:** Topotecan
- **DRUG:** Cyclophosphamide
- **DRUG:** Vincristine
- **DRUG:** Doxorubicin
- **DRUG:** Ifosfamide
- **DRUG:** Etoposide
- **DRUG:** Cisplatin
- **DRUG:** Methotrexate

## Key facts

- **NCT ID:** NCT07321912
- **Lead sponsor:** Milton S. Hershey Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-01
- **Primary completion:** 2031-04-01
- **Final completion:** 2036-04-01
- **Target enrollment:** 406 (ESTIMATED)
- **Last updated:** 2026-01-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07321912

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07321912, "Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07321912. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*